



Friulchem newsletter

APRIL 28TH, 2017

V
E
T
E
R
I
N
A
R
Y

Exclusive worldwide license for FC-Cubes

Friulchem S.p.A. has finalized an exclusive worldwide license, development & supply agreement for some therapeutic categories with the US company Skyline Vet Pharma involving its soft chew technology.

The novel manufacturing method (patent pending in different countries) provides chunk (called FC-cubes) with **100% of prehension and 99% of palatability, full control on composition homogeneity, weight and stability** of active ingredients, but without the drawbacks of a production by extrusion. The first product is under development and the project has been discussed with the CVM at the FDA.

Skyline Vet Pharma was co-founded by animal health and animal biology industry veterans Serge Martinod, D.V.M., Ph.D., as the company's chief executive officer, and George Murphy, who serves as vice president. The company is developing products to address critical needs in the companion animal health industry as today's pet owners expect veterinarians to provide pet health care nearly on par with human health care.

Recently AgTech Accelerator Makes First Animal Health Industry Investment in Skyline Vet Pharma with \$5 Million Series A Financing.

Friulchem S.p.A. is a private chemical-pharmaceutical company based in Italy, dealing with research, development and production of original & generic pharmaceutical products for both human and veterinary fields.

During the years, Friulchem has incremented its field of action adding to veterinary services (micronization, granulation, blending, spray-drying, nutraceuticals) the self-development of veterinary drug products and feed for animals, thanks to the strengthening of the internal R&D laboratory.

This new agreement will allow Friulchem S.p.A. to expand its veterinary line for the care of cats, dogs, and horses.

FRIULCHEM S.p.A.
Disma Giovanni Mazzola
President



Contact us:

mail: friulchem@friulchem.com